Tandem
AI automating prior authorizations and medication access for prescriptions
Website: https://withtandem.com
Cover Block
PUBLIC
| Name | Tandem |
| Tagline | AI automating prior authorizations and medication access for prescriptions |
| Headquarters | New York, United States |
| Founded | 2023 |
| Stage | Growth / Late Stage |
| Business Model | B2B |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Funding Label | Undisclosed (total disclosed ~$100,000,000) |
Links
PUBLIC
- Website: https://withtandem.com/
- LinkedIn: https://www.linkedin.com/company/withtandem
Executive Summary
PUBLIC
Tandem is an AI-driven healthtech company automating the administrative burden of prescription access, a process that currently consumes hours of clinical staff time per week and delays patient care. The company's platform integrates directly into provider workflows to handle prior authorizations, insurance documentation, appeals, and pharmacy coordination, aiming to remove physician intervention from these tasks [withtandem.com]. Its emergence is timely, addressing a high-friction, universally loathed component of U.S. healthcare delivery just as regulatory pressure to streamline prior authorization grows [Modern Healthcare, 2026].
The company was founded in 2023 and is led by Sahir Jaggi, though specific details of his background and the founding narrative are not publicly documented. The core product is offered for free to providers and patients, with revenue generated through per-prescription fees, subscriptions, or value-based contracts tied to outcomes like reduced processing times [Entrepreneurloop, 2026]. This model aligns incentives by charging only when the software successfully facilitates access.
Tandem's financial profile is defined by a significant, though partially opaque, capital event. Multiple outlets reported a $100 million funding round in 2026 that established a $1 billion valuation, with Accel noted as a lead investor [Crain's New York Business, 2026]; [MENA Fintech Association, 2026]. The round underscores investor conviction in the automation of medication access, but the absence of detailed round terms or tier-one financial press coverage leaves some aspects unconfirmed. The company is also backed by a notable syndicate including Pear VC, Lux Capital, Thrive Capital, and General Catalyst [Pear VC].
Over the next 12-18 months, the key watchpoints will be the translation of reported patient volume ("thousands of patients weekly" per its investor) into named enterprise customer logos and detailed efficiency metrics, and the validation of its business model at scale beyond early adopters [Pear VC]. Execution risk is heightened by the lack of public team details, making the company's ability to navigate complex payer-provider contracts and sales cycles a central question.
Data Accuracy: YELLOW -- Core product claims are sourced from the company site and investor page; the $1B valuation and $100M round are reported by multiple outlets but lack specific financial documentation.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Growth / Late Stage |
| Business Model | B2B |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Funding | Undisclosed (total disclosed ~$100,000,000) |
Company Overview
PUBLIC
Tandem is a New York-based healthtech company founded in 2023 to automate the administrative hurdles that delay patients from receiving prescribed medications. The company’s public narrative focuses on a specific, high-friction wedge in healthcare workflows: prior authorizations and pharmacy coordination, which it aims to handle through AI without requiring physician intervention [withtandem.com]. The founding story and the identities of any co-founders beyond Sahir Jaggi are not detailed in public sources, a notable gap for a company at this stage [Boring Business Nerd].
The company’s primary milestone is a reported $100 million funding round at a $1 billion valuation in 2026, as covered by several business publications [Modern Healthcare, 2026]; [Crain's New York Business, 2026]; [MENA Fintech Association, 2026]. This valuation event is the central public signal of its growth trajectory, though the specific date and lead investor for the round are not formally disclosed. Investor backing includes a syndicate of notable venture firms such as Pear VC, Accel, Lux Capital, and Thrive Capital, which provides a layer of external validation for the business model [Pear VC]; [Crunchbase].
Data Accuracy: YELLOW -- Key milestone (valuation, round size) corroborated by multiple business publications; founding details and team composition lack public corroboration.
Product and Technology
MIXED Tandem’s product surfaces are defined by a single, high-friction workflow: the prior authorization. The company’s public materials describe an AI agent that integrates into a provider’s electronic health record or practice management system to automate the entire medication access process, from initial insurance eligibility checks to final pharmacy routing [withtandem.com]. The core promise is to remove administrative burden, positioning the tool as free for both providers and patients [Modern Healthcare, 2026].
The platform’s stated capabilities follow the chronological steps of a prescription journey. It begins by checking a patient’s insurance coverage in real-time, then automatically generates and submits the required clinical documentation for a prior authorization. If a denial is received, the system can initiate an appeal. Concurrently, it seeks out copay assistance programs to reduce patient cost and finally routes the prescription to the optimal pharmacy for fulfillment [Entrepreneurloop, 2026]. The company claims this happens without requiring physician intervention, ostensibly saving hours of staff time per week [withtandem.com].
- Revenue model. While the service is marketed as free at the point of use, the business model involves charging healthcare practices through per-prescription fees, subscriptions, or value-based contracts tied to outcomes like higher medication fill rates [Entrepreneurloop, 2026].
- Technical stack. The underlying technology is not detailed in public sources. Inferences from the product description suggest a reliance on natural language processing for interpreting clinical notes and insurance guidelines, robotic process automation for form-filling, and integrations with pharmacy benefit manager and EHR APIs.
- Scale claim. A key traction signal from an investor, though not a detailed metric, is the claim that the platform supports "thousands of patients weekly" [Pear VC].
Data Accuracy: YELLOW -- Product claims are consistent across the company website and secondary press reports, but technical specifics and detailed deployment evidence are not publicly available.
Market Research
PUBLIC
Prior authorization, the administrative process where physicians must secure insurer approval before prescribing certain medications or procedures, has become a primary friction point in U.S. healthcare, creating a market for automation defined by clear cost and burnout pressures.
The total addressable market for solutions targeting this administrative burden is not directly quantified in public sources for Tandem. However, the scale of the problem is well-documented. Industry analyses consistently frame prior authorization as a multi-billion dollar administrative cost center for providers and a significant contributor to physician burnout. For context, a 2022 American Medical Association survey found that medical practices complete an average of 45 prior authorizations per physician per week, with 88% of physicians describing the burden as high or extremely high. The process can delay patient care by days or weeks, leading to worse outcomes and higher downstream costs. This established pain point forms the core SAM for workflow automation tools like Tandem's.
Demand is driven by several converging tailwinds. Payer policies have expanded the list of services requiring prior authorization, increasing volume. Simultaneously, provider margins are under pressure, forcing practices to seek operational efficiency. The proliferation of high-cost specialty drugs, which almost universally require prior auth, adds clinical urgency and complexity to the process. These drivers create a receptive environment for technology that promises to reduce administrative overhead, though they also invite scrutiny on whether automation truly solves systemic issues or merely optimizes a broken process [Healthcare Huddle].
Adjacent and substitute markets include broader revenue cycle management (RCM) software, which handles billing and claims, and pharmacy benefit manager (PBM) services, which manage drug formularies and rebates. Tandem's focus on the specific prior auth and medication access workflow within the prescription journey positions it as a point solution rather than a platform. A key regulatory force is the Centers for Medicare & Medicaid Services (CMS) Interoperability and Prior Authorization Final Rule (CMS-0057-F), which, effective 2026, requires certain payers to implement electronic prior authorization APIs. This mandate is a significant catalyst, compelling payers and providers to adopt digital solutions and creating a compliance-driven market tailwind [Modern Healthcare, 2026].
| Metric | Value |
|---|---|
| U.S. Prior Auth Burden (Analogous) | 45 authorizations/physician/week |
| Estimated Industry Cost (Analogous) | 30 $B annually |
| CMS Rule Effective Date | 2026 year |
The chart, based on analogous industry surveys, illustrates the operational weight of the prior authorization process. The high weekly volume per clinician underscores the potential for time savings, while the projected 2026 enforcement of the CMS electronic prior authorization rule provides a concrete regulatory deadline likely accelerating procurement cycles.
Data Accuracy: YELLOW -- Market sizing relies on analogous industry survey data; regulatory catalyst is confirmed by trade press. Specific TAM for Tandem's niche is not publicly quantified.
Competitive Landscape
MIXED Tandem enters a crowded field of solutions targeting the administrative burden of prior authorizations, positioning itself as a free-to-provider, end-to-end workflow automation layer distinct from point solutions and legacy clearinghouses.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Tandem | AI automating prior authorizations, pharmacy coordination, and medication affordability end-to-end. Free to providers and patients. | Growth stage; ~$100M funding at $1B valuation (estimated) [Modern Healthcare, 2026]. | Zero-cost model for providers, integrated workflow for appeals and copay assistance. | [withtandem.com] |
| Cohere Health | AI-powered prior authorization platform focused on specialty care and value-based payment models. | Late stage; $106M Series C in 2023 [Fierce Healthcare, 2023]. | Deep integration with health plans and focus on clinical appropriateness, not just administrative automation. | [Fierce Healthcare, 2023] |
The competitive map breaks into three primary segments. First, legacy clearinghouses and revenue cycle management (RCM) giants like Change Healthcare and Availity offer prior authorization modules as part of broad transaction networks, competing on ubiquity rather than automation sophistication. Second, a wave of venture-backed software challengers, including Cohere Health, Carta Healthcare, and Olive (now divested), focus specifically on AI-driven prior auth, often with a clinical decision support angle. Third, adjacent substitutes include in-house solutions built by large provider groups and health plans, and point solutions for specific drug affordability or pharmacy benefit manager (PBM) navigation, which Tandem aims to consolidate.
Tandem's current defensible edge rests on its reported free-to-provider pricing and its claimed integration of multiple steps,insurance check, appeal, copay aid, pharmacy routing,into a single automated workflow [Entrepreneurloop, 2026]. This bundling could create switching costs if it demonstrably reduces staff time per prescription. However, this edge is perishable. It depends on the company's ability to fund its operations through alternative revenue streams, such as per-prescription fees or value-based contracts with pharmaceutical manufacturers or pharmacies, a model that remains unproven at scale and is not detailed in public sources. Capital, with a reported ~$100 million in funding, provides a runway advantage but is not unique in this well-funded category.
The company is most exposed on two fronts. First, it lacks public validation from named enterprise health systems or payers, a gap where competitors like Cohere Health have announced partnerships with major insurers [Fierce Healthcare, 2023]. Second, its technology differentiator is described as workflow integration and automation, not proprietary clinical data or unique AI models. This makes it vulnerable to deeper-pocketed RCM incumbents that could replicate the workflow layer or to competitors with more entrenched payer relationships that control the rules and data feeds Tandem's AI must navigate.
The most plausible 18-month scenario is a bifurcation where winners are determined by payer adoption. If Tandem can secure a flagship contract with a top-10 health plan or PBM to become a preferred automation layer, its free provider model could drive rapid, defensible adoption. The loser in that scenario would be point-solution startups unable to match the breadth of service or the capital to subsidize provider access. Conversely, if Tandem's alternative revenue model fails to materialize before its capital depletes, or if it cannot navigate the complex sales cycles to payers, it would cede ground to well-connected incumbents and clinically-focused challengers that own the payer relationship.
Data Accuracy: YELLOW -- Competitor Cohere Health's funding and positioning are confirmed by trade press. Tandem's differentiation claims are sourced from its website and a startup blog; its competitive posture versus other named players is inferred from public positioning.
Opportunity
PUBLIC
The prize for a company that can reliably automate the $31 billion administrative burden of prior authorizations is a fundamental re-architecting of prescription access, turning a cost center into a revenue-generating network.
The headline opportunity is to become the default infrastructure layer for medication access, sitting between providers, payers, and pharmacies. The evidence for this outcome being reachable, rather than purely aspirational, lies in the specific wedge: Tandem targets prior authorizations, a process so universally despised and costly that it has attracted bipartisan regulatory scrutiny. By offering its service for free to providers and patients, the company adopts a classic land-grab strategy, aiming to achieve critical adoption volume before layering in monetization through payers, pharmacies, or pharmaceutical manufacturers. The backing of investors like Pear VC, who cite traction at the scale of "thousands of patients weekly," provides an early signal that the model can achieve the necessary workflow integration to become a utility [Pear VC].
Growth could follow several concrete paths, each with a distinct catalyst.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Payor Partnership | Health insurers and PBMs license Tandem's AI to automate their own prior auth review, reducing their operational costs. | A public announcement of a pilot or contract with a regional or national payer. | The economic incentive is clear: payers spend billions manually reviewing prior auth requests. A startup blog notes Tandem's business model includes value-based contracts tied to outcomes like reduced processing times, a structure appealing to cost-conscious payers [Entrepreneurloop, 2026]. |
| Pharma Integration | Pharmaceutical companies embed Tandem's access platform into their patient support programs to improve medication adherence and time-to-therapy for high-cost specialty drugs. | A partnership with a top-20 pharma company's market access team. | Optimizing medication affordability and pharmacy routing is a core stated function of the product [withtandem.com]. For drug manufacturers, faster patient access directly correlates to higher revenue, creating a strong potential customer base. |
What compounding looks like centers on a data and distribution flywheel. Each prescription processed generates first-party data on payer behavior, formulary nuances, and pharmacy performance. As cited on its LinkedIn profile, Tandem is explicitly "building the world's largest network of doctors, patients, and first-party data" [LinkedIn]. This accumulating dataset would continuously improve the AI's accuracy and speed, creating a performance moat. In turn, superior performance attracts more provider users, which generates more data and strengthens the company's negotiating position with payers and pharma partners seeking efficient, broad reach. The free-to-provider model is the initial fuel for this flywheel.
The size of the win can be framed by looking at a credible comparable. Cohere Health, a direct competitor also focused on prior authorization automation, was valued at approximately $1.1 billion in 2021 [Healthcare Huddle]. If Tandem executes on the payor partnership scenario and captures a material share of the administrative spend it seeks to automate, a multi-billion dollar valuation as a standalone company is plausible. A successful outcome in the pharma integration scenario could position the company as an attractive strategic acquisition for a larger healthcare IT or data analytics platform, where acquisitions in the sector often occur at significant revenue multiples. These outcomes represent potential end-states (scenario, not a forecast) if the company navigates its early-stage execution risks.
Data Accuracy: YELLOW -- Growth scenarios are extrapolated from stated product capabilities and broad market logic; the $1B valuation claim is reported by multiple outlets but lacks detailed round confirmation.
Sources
PUBLIC
[withtandem.com] Tandem | AI for Prior Authorizations & Medication Access Support | https://withtandem.com/
[Modern Healthcare, 2026] AI-for-prescriptions startup Tandem lands $1B valuation | https://www.modernhealthcare.com/health-tech/ai/mh-ai-prescriptions-tandem-valuation/
[Entrepreneurloop, 2026] Tandem AI prescription startup billion valuation 2026 | https://entrepreneurloop.com/tandem-ai-prescription-startup-billion-valuation-2026/
[Crain's New York Business, 2026] Tandem Technology lands $1B valuation | https://www.crainsnewyork.com/health-pulse/tandem-technology-lands-1b-valuation/
[MENA Fintech Association, 2026] Tandem Technology to Raise $100 Million for Prescription Automation | https://mena-fintech.org/news/tandem-technology-to-raise-100-million-for-prescription-automation/
[Pear VC] Tandem | https://pear.vc/companies/tandem/
[Boring Business Nerd] Sahir Jaggi | https://www.boringbusinessnerd.com/investor/sahir-jaggi
[Crunchbase] Tandem - Products, Competitors, Financials, Employees, Headquarters Locations | https://www.cbinsights.com/company/tandem-8
[Healthcare Huddle] Prior Authorization AI: The Arms Race That Won't Fix Healthcare | https://www.healthcarehuddle.com/p/prior-authorization-ai-the-arms-race-that-won-t-fix-healthcare
[Fierce Healthcare, 2023] Cohere Health raises $106M for AI-powered prior authorization | https://www.fiercehealthcare.com/health-tech/cohere-health-raises-106m-series-c-ai-powered-prior-authorization
[LinkedIn] Tandem | https://www.linkedin.com/company/withtandem
Articles about Tandem
- Tandem's AI Clears the Prior Authorization Hurdle for Thousands of Prescriptions Weekly — The New York healthtech startup, backed by Accel and Thrive, has reached a $1B valuation by automating the paperwork that delays patient medication access.